Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) had a rough 2011. If the pre-market trading indications manage to last throughout the day, then it appears that Teva could be off to a great start in 2012. The company just announced that it will have a new Chief Executive Officer. Whether you look at Teva for its generic gains or its branded products, this may matter. The company’s current CEO will retire in May and will be replaced by Jeremy Levin upon retirement. Teva was well above $50 throughout much of early 2011 and ended up going under $40.00 before recovering. Shares closed out at $40.36 on Friday and the stock is indicated up 3.6% at $41.82 so far this Tuesday morning to start of 2012.
JON C. OGG
Top Gaining Stocks
Top Losing Stocks